Cargando…
Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
Long-term maintenance therapy for COPD is evolving rapidly. Dual bronchodilation with new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination inhalers were introduced over the past 2 years. In clinical trials, these inhalers significantly improved lung f...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5491575/ https://www.ncbi.nlm.nih.gov/pubmed/28694698 http://dx.doi.org/10.2147/COPD.S138006 |